Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy.

BMC cancer - 30 Aug 2017

Hilal Talal, Nakazawa Mary, Hodskins Jacob, Villano John L, Mathew Aju, Goel Guarav, Wagner Lars, Arnold Susanne M, DeSimone Philip, Anthony Lowell B, Hosein Peter J

Abstract excerpt

BACKGROUND: Describe a single-center real-world experience with comprehensive genomic profiling (CGP) to identify genotype directed therapy (GDT) options for patients with malignancies refractory to standard treatment options. METHODS: Patients who had CGP by a CLIA-certified laboratory between November 2012 and December 2015 were included. The medical records were analyzed retrospectively after Institutional...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child, Preschool

Share to Clinical Trials as Topic

Share to Genomics

Share to Neoplasms

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 28854908
DOI: 10.1186/s12885-017-3587-8
PMCID: PMC5577820

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy.PMID 28854908Read ↗

Application of genotype-guided cancer therapy in solid tumors.Semantic proximity Read ↗

Integrating genomics into clinical pediatric oncology using the molecular tumor board at the Memorial Sloan Kettering Cancer CenterSemantic proximity Read ↗

Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.Semantic proximity Read ↗

Comprehensive genomic profiling for patients with chemotherapy‐naïve advanced cancerSemantic proximity Read ↗

Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.Semantic proximity Read ↗

Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trialSemantic proximity Read ↗

An institutional review of genomic sequencing in pediatric solid tumors.Semantic proximity Read ↗

Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.Semantic proximity Read ↗

Profiling critical cancer gene mutations in clinical tumor samples.Semantic proximity Read ↗

Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven OncologySemantic proximity Read ↗

High clinical utility of comprehensive multi-omic molecular profiling of rare and hard-to-diagnose pediatric tumorsSemantic proximity Read ↗

Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.